Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Actinium Pharmaceuticals (ATNM) Stock Price & Analysis

2,293 Followers

ATNM Stock Chart & Stats

$1.64$0.05(3.14%)
At close: 4:00 PM EST
$1$1.25$1.5Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$1.55 - $1.64
52-Week Range
$0.74 - $1.72
Previous Close
$1.59
Volume
N/A
Average Volume (3M)
234.10K
Market Cap
$49.99M
Enterprise Value
-$3.88M
Total Cash (Recent Filing)
$36.47M
Total Debt (Recent Filing)
$1.34M
Price to Earnings (P/E)
4.6
Beta
1.66
Next Earnings
Nov 23, 2026 (Est.)
EPS Estimate
-0.24
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Conservative leverage gives Actinium greater financial flexibility than many biotechnology peers and limits near-term interest and refinancing pressure. The stronger equity base also improves solvency capacity while the company funds clinical development and works toward potential future commercialization.

Actimab-A Patent And Manufacturing Expansion

Broader intellectual-property protection can extend the commercial runway for Actimab-A and strengthen differentiation in targeted radiotherapy. Added manufacturing capacity supports clinical execution and reduces an operational bottleneck as the program approaches important milestones in late 2026 and 2027.

Experienced CFO Appointment

A CFO with experience spanning regulatory approval, commercial launch, capital markets and strategic transactions may improve financial execution as Actinium advances its pipeline. His background is relevant to funding, investor communication and potential partnering around the company’s radiotherapy assets.

Bears Say

Persistent Cash Burn

Deeply negative operating and free cash flow means the business is not currently self-funding its development activities, even after the latest reported net-income improvement. If the burn persists, Actinium may need additional financing, increasing dilution or funding pressure over the next several quarters.

Thin And Volatile Profitability

The sharp swing to positive net income is encouraging, but the extremely thin gross margin provides little cushion to absorb operating costs or revenue variability. Multiple prior loss-making years and volatile margins make the latest earnings improvement difficult to treat as a durable measure of underlying profitability.

NYSE American Compliance Risk

Continued noncompliance with exchange standards creates a structural corporate risk that extends beyond short-term market sentiment. Failure to meet the remediation requirements could lead to delisting, potentially reducing market access and complicating future capital raising needed to fund clinical programs.

Actinium Pharmaceuticals News

ATNM FAQ

What was Actinium Pharmaceuticals’s price range in the past 12 months?
Actinium Pharmaceuticals lowest stock price was $0.74 and its highest was $1.72 in the past 12 months.
What is Actinium Pharmaceuticals’s market cap?
Actinium Pharmaceuticals’s market cap is $49.99M.
When is Actinium Pharmaceuticals’s upcoming earnings report date?
Actinium Pharmaceuticals’s next earnings report is estimated for Nov 23, 2026 (not yet confirmed), which is in 8 days.
How were Actinium Pharmaceuticals’s earnings last quarter?
Actinium Pharmaceuticals released its earnings results on Mar 13, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.187 by -$0.003.
Is Actinium Pharmaceuticals overvalued?
According to Wall Street analysts Actinium Pharmaceuticals’s price is currently Undervalued.
Does Actinium Pharmaceuticals pay dividends?
Actinium Pharmaceuticals does not currently pay dividends.
What is Actinium Pharmaceuticals’s EPS estimate?
Actinium Pharmaceuticals’s EPS estimate is -0.24.
How many shares outstanding does Actinium Pharmaceuticals have?
Actinium Pharmaceuticals has 31,441,437 shares outstanding.
What happened to Actinium Pharmaceuticals’s price movement after its last earnings report?
Actinium Pharmaceuticals reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.187. Following the earnings report the stock price went down -1.77%.
Which hedge fund is a major shareholder of Actinium Pharmaceuticals?
Hedge funds hold Actinium Pharmaceuticals shares: the largest hedge-fund position in Actinium Pharmaceuticals is 71,883,876 shares, and hedge funds increased their holdings by 24.7K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology